Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
Imara Inc. (Nasdaq: IMRA) will host a conference call on August 6, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results and recent business updates. The call can be accessed domestically at 1 (833) 519-1307 or internationally at +1 (914) 800-3873 with conference ID 6499377. Imara is focused on developing IMR-687, a potential treatment for sickle cell disease and beta-thalassemia. The drug is a selective inhibitor of PDE9 and aims to provide a multimodal mechanism of action, improving patient outcomes.
- Imara is advancing IMR-687, a potential disease-modifying treatment for sickle cell disease and beta-thalassemia.
- The company is dedicated to developing innovative therapeutics for rare inherited genetic disorders.
- None.
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 6, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and review recent business highlights.
A live webcast will be available under “Events and Presentations” in the Investors section of the company's website. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 6499377. A replay of the webcast will be archived on the Imara website following the presentation.
About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.
Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com
Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com
FAQ
When will Imara Inc. discuss its Q2 2021 financial results?
What is IMR-687 developed by Imara?
How can I access the conference call for Imara's financial results?
